JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Scope & Guideline

Advancing Knowledge in Mammary Gland Research

Introduction

Welcome to the JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1083-3021
PublisherSPRINGER/PLENUM PUBLISHERS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1996 to 2024
AbbreviationJ MAMMARY GLAND BIOL / J. Mammary Gland Biol. Neoplasia
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address233 SPRING ST, NEW YORK, NY 10013

Aims and Scopes

The JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA focuses on the intricate biology of the mammary gland and its implications in neoplastic processes, particularly breast cancer. The journal aims to contribute to a deeper understanding of mammary gland development, physiology, and pathology through innovative research and methodologies.
  1. Mammary Gland Development and Physiology:
    Research on the biological processes underlying mammary gland development, including cellular differentiation, hormonal regulation, and physiological functions.
  2. Breast Cancer Biology and Pathophysiology:
    Investigation into the molecular and cellular mechanisms of breast cancer, including tumor microenvironment interactions, signaling pathways, and genetic factors.
  3. Preclinical Models and Experimental Techniques:
    Development and utilization of various models (e.g., murine, bovine) and experimental techniques (e.g., organoids, 3D bioprinting) to study mammary gland biology and breast cancer.
  4. Immune Response and Cancer Interaction:
    Exploration of the immune landscape in the context of mammary gland biology and breast cancer, including immune cell contributions to tumor development and progression.
  5. Comparative Studies Across Species:
    Comparative analyses of mammary gland biology and breast cancer across different species to enhance translational research and understanding of the disease.
Recent publications in the JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA indicate exciting trends and emerging themes that reflect the evolving landscape of research in mammary gland biology and breast cancer. These themes highlight innovative methodologies and interdisciplinary approaches.
  1. Single-Cell Analysis Techniques:
    There is a notable increase in studies utilizing single-cell transcriptomic and spatial analysis to understand cellular heterogeneity in mammary glands and breast tumors, which is critical for personalized medicine.
  2. 3D Bioprinting and Spatial Engineering:
    Emerging methodologies such as 3D bioprinting for modeling mammary epithelial cell cultures are gaining attention, allowing for more sophisticated in vitro studies of tissue architecture and function.
  3. Immunotherapy and the Tumor Microenvironment:
    Research focusing on the immune microenvironment and its role in breast cancer progression and treatment response is becoming increasingly prominent, reflecting a shift towards immunotherapy strategies.
  4. One Health Approach to Breast Cancer:
    The exploration of male breast cancer within a One Health framework indicates a growing interest in understanding breast cancer from a broader biological and societal perspective.
  5. Comparative Oncology:
    Studies comparing mammary gland biology and cancer across species, particularly between canines and humans, are on the rise, emphasizing translational research opportunities and insights.

Declining or Waning

While the JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA has consistently focused on core areas of mammary gland biology and breast cancer, some themes appear to be declining in prominence. This may reflect shifts in research priorities or advancements in methodologies that have rendered certain topics less central.
  1. Traditional In Vivo Models:
    Research relying heavily on traditional in vivo models (e.g., rat models) for breast cancer studies may be waning as more advanced techniques such as organoid systems and patient-derived xenografts gain traction.
  2. Basic Histological Techniques:
    Studies focusing exclusively on basic histological analyses without integrating advanced imaging or molecular techniques are becoming less frequent, as the field moves towards more comprehensive approaches.
  3. Single-agent Chemotherapy Studies:
    Research concentrating solely on the efficacy of single-agent chemotherapies in breast cancer may be declining as the focus shifts toward combination therapies and personalized medicine approaches.

Similar Journals

Oncogenesis

Innovating insights into the biology of cancer.
Publisher: SPRINGERNATUREISSN: 2157-9024Frequency: 1 issue/year

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

INTERNATIONAL JOURNAL OF ONCOLOGY

Pioneering innovative practices in cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Transforming cancer research into clinical solutions.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Journal of the National Cancer Center

Connecting Researchers to Combat Cancer Effectively.
Publisher: ELSEVIERISSN: 2667-0054Frequency: 4 issues/year

Journal of the National Cancer Center, published by Elsevier, serves as a pivotal platform in the fields of Cancer Research, Hematology, and Oncology. With an ISSN of 2667-0054, this esteemed journal is recognized for its exceptional quality, achieving a Q1 ranking in all categories as of 2023. Its impressive Scopus rankings place it among the top journals in its field, notably holding rank #11 in Medicine - Hematology and rank #36 in Medicine - Oncology. Addressed from Amsterdam, Netherlands, the journal aims to disseminate cutting-edge research and innovative findings that advance the understanding and treatment of cancer, bridging gaps between laboratory discoveries and clinical applications. Although it follows a subscription model, the journal's commitment to accessibility ensures that valuable knowledge reaches healthcare professionals and researchers globally. By fostering collaboration and facilitating knowledge exchange, the Journal of the National Cancer Center is indispensable for those dedicated to combating cancer and enhancing patient care.

Cancer Reports

Advancing cancer research for a healthier tomorrow.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

CANCER SCIENCE

Pioneering discoveries in cancer biochemistry and genetics.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

NATURE REVIEWS CANCER

Navigating the Complexities of Cancer Science
Publisher: NATURE PORTFOLIOISSN: 1474-175XFrequency: 12 issues/year

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.

Annual Review of Cancer Biology

Elevating Understanding in Cancer Research
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

CANCER INVESTIGATION

Illuminating pathways in oncology through peer-reviewed excellence.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Genes & Diseases

Exploring the molecular pathways of health and illness.
Publisher: KEAI PUBLISHING LTDISSN: 2352-4820Frequency: 6 issues/year

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.